The CRASH-19 trial is a multinational, open-label, factorial, randomised trial in adults hospitalised with suspected or confirmed acute COVID-19 infection.
We will evaluate the effect of aspirin (150mg once daily), losartan (100mg once daily), and simvastatin (80mg once daily) in patients with COVID-19 infection. Eligible patients will be randomly allocated to one of eight study arms (aspirin only; losartan only; simvastatin only; aspirin and losartan; aspirin and simvastatin; losartan and simvastatin; aspirin, losartan and simvastatin; standard care only). Trial treatments are given in addition to the usual standard of care at the study hospital. Treatment will be started as soon as possible after randomisation and will continue until death, discharge or 28 days after randomisation, whichever occurs first.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
University College Hospital
Ibadan, Oyo State, Nigeria
Shifa Tameer-e-Millat University
Rawalpindi, Pakistan
Death
Cause of death will be described
Time frame: up to 28 days of randomisation
Myocardial infarction
Time frame: up to 28 days of randomisation
Congestive cardiac failure
Time frame: up to 28 days of randomisation
Severe cardiac arrythmia
Time frame: up to 28 days of randomisation
Myocarditis
Time frame: up to 28 days of randomisation
Respiratory failure including ARDS
Time frame: up to 28 days of randomisation
Viral pneumonitis
Time frame: up to 28 days of randomisation
Acute renal failure
Time frame: up to 28 days of randomisation
Sepsis
Time frame: up to 28 days of randomisation
Stroke
Time frame: up to 28 days of randomisation
Gastrointestinal bleeding
Time frame: up to 28 days of randomisation
Receipt of non invasive or mechanical ventilation
Time frame: up to 28 days of randomisation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ability to self care at hospital discharge
Time frame: up to 28 days of randomisation